Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Aetna    AET

AETNA (AET)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

Aetna : Profit Rises; Firm Stays Mum About CVS -- WSJ

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/01/2017 | 07:48am CEST
By Anna Wilde Mathews and Allison Prang 

This article is being republished as part of our daily reproduction of WSJ.com articles that also appeared in the U.S. print edition of The Wall Street Journal (November 1, 2017).

Aetna Inc. posted increased profit but a decline in revenue for its latest quarter as the insurer highlighted moves to reposition its offerings and set itself up for long-term growth.

During a call with analysts to discuss earnings, Aetna executives declined to address a report in The Wall Street Journal that CVS Health Corp. was in talks to purchase the company for more than $66 billion.

Chief Executive Mark T. Bertolini said the company won't "comment on rumors or speculation." He did, however, say that Aetna aims to announce its plans for the future of its pharmacy-benefit contract with CVS by the middle of next year, and that CVS's agreement to service the new pharmacy-benefit manager being launched by Anthem Inc. is "not a problem for us." The existing Aetna contract with CVS goes through 2022, but Aetna has the ability to opt out at the start of 2020.

Mr. Bertolini also said Aetna is poised to plunge back into sales of short-term health insurance if the Trump administration removes a cap limiting such plans to three months' duration, a move encouraged by a recent executive order.

He said Aetna is "already all over that," and, once regulations come out fleshing out the executive order, "we will be prepared when we have the opportunity to act." But he said Aetna is looking at the short-term plans rather than so-called skinny coverage that would fall short of the protections of full health insurance and can create "moral harm," he said. Skinny coverage is a term that is often used to describe products such as indemnity plans, which pay a set amount toward certain medical services such as hospital stays.

Aetna Chief Financial Officer Shawn M. Guertin said in an interview that the company was looking at "limited-term products, not limited-benefit products."

Mr. Bertolini also played up Aetna's long-term growth trajectory as a stand-alone company, despite several moves that would be blows to its revenue in 2018. Aetna's continued retreat from the Affordable Care Act exchanges, the sale of its life and disability business and some pullbacks in Medicaid will affect revenue next year, the company said.

Aetna said the impact on profit would be less, particularly given the losses on the ACA business, though like other insurers it said earnings next year will take a hit from the expected return of the ACA tax on health plans, which had been suspended.

Looking forward, Mr. Bertolini emphasized Aetna's growth in Medicare, including its performance in the federal program's quality rankings, and investments Aetna is making in data analytics. Aetna also said it is looking for growth in Medicaid over the long term.

Though Mr. Bertolini didn't discuss CVS, he did talk about efforts to get closer to consumers by providing care in settings cheaper than a hospital and helping them avoid emergency-room visits and other costly care.

He said Aetna didn't need to own health-care providers and services. In a previous earnings call, he had discussed CVS's drugstores as one pathway to providing contact and support for consumers.

Aetna has said it is exiting the ACA exchanges next year, but Mr. Bertolini said that if the business "gets right and stable, we'll look at reconsidering on how we get in."

Aetna on Tuesday again raised its profit forecast for 2017, predicting adjusted earnings per share of $9.75. The company previously estimated per-share earnings between $9.45 and $9.55.

Total adjusted revenue at Aetna fell 5% to $14.95 billion as fewer people were on the company's ACA plans and from the temporary suspension of the ACA health-insurance tax. Analysts were expecting revenue of $15.13 billion. The company had predicted individual ACA plans would lose more than $200 million in 2017.

Aetna posted net income of $838 million for the third quarter, up 39% from a year earlier. On an adjusted basis, net income rose 11% to $814 million. Adjusted earnings per share rose to $2.45, beating analysts' estimates of $2.09 a share. In the prior-year quarter, Aetna earned $2.07 on an adjusted per-share basis.

Write to Anna Wilde Mathews at anna.mathews@wsj.com and Allison Prang at allison.prang@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AETNA
09/21FEDEX GROUND HAS OPENED A SPRAWLING : Here's What You Need To Know
AQ
09/21FEDEX GROUND IS OPENING A SPRAWLING : Here's What You Need To Know
AQ
09/21Correction to Data-Breach Notification Rules Article on Sept. 18 -- Journal R..
DJ
09/19AETNA : Announces CEO to Lead New Aetna : Medicaid Plan in Kansas
BU
09/18AETNA : Names Richard Weiss Market President of Florida
BU
09/18AETNA : Stop the looming health care 'oligopoly'
AQ
09/17CVS HEALTH : U.S. review of CVS deal for Aetna may end soon
RE
09/17AETNA : Stop looming health care 'oligopoly'
AQ
09/13AETNA : Announces Additional Hurricane Florence Resources
BU
09/12AETNA : CA Judge SLAPPs Aetna Lawsuit Against Consumer Watchdog and Whatley Kall..
AQ
More news
News from SeekingAlpha
09/18Aetna names Richard Weiss Market President of Florida 
09/13Merger Arbitrage In One Place (Part 3) 
09/11Prescription drug middlemen behind cost increases - Bloomberg 
09/07Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2018 Update 
09/05WSJ : DoJ nearing antitrust OK of CVS-Aetna, Cigna-Express Scripts mergers 
Financials ($)
Sales 2018 61 404 M
EBIT 2018 5 212 M
Net income 2018 3 800 M
Debt 2018 -
Yield 2018 0,96%
P/E ratio 2018 17,85
P/E ratio 2019 17,04
Capi. / Sales 2018 1,09x
Capi. / Sales 2019 1,03x
Capitalization 66 878 M
Chart AETNA
Duration : Period :
Aetna Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AETNA
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Average target price 202 $
Spread / Average Target -0,97%
EPS Revisions
Managers
NameTitle
Mark T. Bertolini Chairman & Chief Executive Officer
Karen S. Lynch President
Margaret M. McCarthy Executive Vice President-Operations & Technology
Shawn M. Guertin CFO, Executive VP & Chief Enterprise Risk Officer
Harold L. Paz Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
AETNA13.24%66 878
UNITEDHEALTH GROUP20.96%256 663
ANTHEM INC21.11%70 843
CIGNA CORPORATION-0.42%49 216
HUMANA36.16%46 531
CENTENE CORPORATION41.47%29 292